ArticleViruses2023
Epidemiological Characteristics and Economic Burden of Dengue in Zhejiang Province, China.
Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The economic burden of dengue: a systematic literature review of unit costs for non-fatal episodes treated in the formal healthcare system.BMC infectious diseases · 2026Pooled it
- Evaluating the economic burden of dengue in Sri Lanka: A systematic review of costs from 2010 to 2024.IJID regions · 2026Review
- Evaluating the effectiveness of different intervention measures for a dengue outbreak in Hangzhou based on a dynamic model.BMC public health · 2026Article
- The overlapping global distribution of dengue, chikungunya, Zika and yellow fever.Nature communications · 2025Article
- An integrated surveillance in Zhejiang Province: ecological and pathogen survey of vectors and reservoir hosts in 2024.Frontiers in veterinary science · 2025Article
- Community-based sustainable vector management strategies in rural areas of Zhejiang Province: criteria development and long-term impact assessment of vector control toward "Four Pest-Free Village" pilot program.Frontiers in veterinary science · 2025Article
- Integrated mosquito control in Matatang village, Northern Zhejiang, China: an effectiveness assessment.Frontiers in public health · 2025Article
- Epidemiological and clinical characteristics of dengue fever in Fuzhou, China, in 2023.BMC infectious diseases · 2024Article
- The Dynamic Relationship between Dengue Virus and the Human Cutaneous Innate Immune Response.Viruses · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue imposes a heavy economic burden on families and society. We used surveillance data reported in 2019 to characterize the dengue epidemic in Zhejiang Province, China, which provided guidance for dengue prevention and control. Dengue epidemics mostly occurred in July to October. People aged 30-44 years, males, and commercial service workers were more likely to suffer from dengue. The epidemic areas were mainly in Hangzhou and Wenzhou. Meanwhile, we assessed the economic cost of dengue in the province from both family and organizational perspectives. The direct economic burden of dengue patients was estimated to be USD 405,038.25, and the indirect economic burden was USD 140,364.90, for a total economic burden of USD 543,213.00. The direct economic burden of dengue patients should be reduced by increasing the coverage and reimbursement of health insurance. Additionally, the total annual cost of dengue prevention and control for the government and organizational sectors was estimated to be USD 7075,654.83. Quantifying the dengue burden is critical for developing disease control strategies, allocating public health resources, and setting health policy priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.